Rigaku Partners with SPERA PHARMA to Boost Pharmaceutical Development

Rigaku Corporation, a Group company of Rigaku Holdings Corporation, and SPERA PHARMA, Inc. (headquarters: Osaka; President & Representative Director: Keitaro Iwaki; hereinafter “SPERA PHARMA”) have initiated a strategic partnership aimed at accelerating and transforming pharmaceutical development by leveraging the two companies’ cutting-edge technologies and extensive expertise.

SPERA PHARMA will use XtaLAB Synergy-ED, an integrated platform for electronic diffraction provided by Rigaku, for contract analytical services, thereby offering customers robust support in pharmaceutical development.

The XtaLAB Synergy-ED incorporates 3D ED/MicroED, which is utilized for the structure analysis of substances, including microscopic crystals and minute quantities of crystalline powder. This sophisticated technology provides sufficiently high resolution to determine atomic-level structures, enabling the detailed elucidation of molecular structures of organic compounds and similar substances.

SPERA PHARMA is currently the world’s only company in the pharmaceutical industry offering contract analytical services with the XtaLAB Synergy-ED. Rigaku will extend technical support to SPERA PHARMA for its contract analytical operations.

Furthermore, the two companies are collaborating closely to advance research utilizing the XtaLAB Synergy-ED and to actively share information on the application methods and analytical technologies.

Through this partnership, Rigaku and SPERA PHARMA aim to provide robust support at the forefront of pharmaceutical development, playing pivotal roles in pioneering the future of medicine.

Related Posts

  • Pharma
  • July 16, 2025
  • 125 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

  • Pharma
  • July 16, 2025
  • 40 views
Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon. Shares of pharmaceutical companies traded flat on Wednesday, July…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.